- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Enzyme Replacement Therapy Market is Expanding Steadily
Future Market Insights recently published research findings that the global enzyme replacement therapy market is predicted to increase at 6.5% CAGR over the forecast period 2018–2028. It also finds the global market for enzyme replacement therapy is expected to exceed $ 13,776.2 million (US dollars) by the end of 2028, attesting the highest growth rate by Japan, which is expected to expand at 12.5% CAGR over 2018–2028. The developing healthcare infrastructure and awareness programs in regions of Asia Pacific and China is expected to play a part in revenue growth for the global enzyme replacement therapy market.
Some key research findings include:
- Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of $ 6,448.3 million (US dollars) between 2018 and 2028
- When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
